Breast Cancer Update

Featuring perspectives from Dr Charles E Geyer Jr, Dr Maryam Lustberg, Dr Rita Nanda and Dr Seth Wander, including the following topics:Breast Cancer Introduction: ESMO 2026; Recent FDA Approvals (0:00)ER-Positive Breast Cancer (5:01)HER2-Positive Breast Cancer (1:19:08)Triple-Negative Breast Cancer (1:48:54)CME information and select publications

Featuring an interview with Dr Erica Mayer, including the following topics:Risk Assessment and Genomic Assays for Hormone Receptor (HR)-Positive, HER2-Negative Localized Breast Cancer (0:00)Investigator Survey Results on Risk Assessment and Genomic Assays (20:07)Adjuvant CDK4/6 Inhibitors for High-Risk, HR-Positive, HER2-Negative Localized Breast Cancer (24:30)Investigator Survey Results on Adjuvant CDK4/6 Inhibitors (30:42)Tolerability and Other Practical Considerations with Adjuvant CDK4/6 Inhibitor Therapy (32:07)Investigator Survey Results on Tolerability and Other Practical Considerations with Adjuvant CDK4/6 Inhibitor Therapy (37:44)Adjuvant Oral Selective Estrogen Receptor Degraders (SERDs) for HR-Positive, HER2-Negative Localized Breast Cancer (39:05)Investigator Survey Results on Adjuvant Oral SERDs (43:02)Discussion of Questions from the Community (45:00)CME information and select publications

Featuring perspectives from Dr Sara M Tolaney, including the following topics:Management of adverse events associated with TROP2-targeting antibody-drug conjugates (0:00)Managing brain metastases in triple-negative breast cancer (6:30)EGFR x HER3-directed bispecific antibodies for metastatic triple-negative breast cancer (mTNBC) (9:11)PD-1/PD-L1 x VEGF-directed bispecific antibodies for mTNBC (12:31)CME information and select publications

Featuring perspectives from Dr Sara M Tolaney, including the following topics:Mechanistic effects and potential resistance mechanisms of antibody-drug conjugates (0:00)First-line treatment of metastatic triple-negative breast cancer (mTNBC) in patients eligible for immunotherapy (7:13)First-line treatment of mTNBC in patients ineligible for immunotherapy (13:02)Antibody-drug conjugates for previously treated HER2-low metastatic breast cancer (19:15)CME information and select publications

Featuring perspectives from Dr David W Cescon, including the following topics:Clinical treatment of BRCA-mutated metastatic triple-negative breast cancer (0:00)CNS activity of TROP2-directed antibody-drug conjugates (5:36)Autoimmune considerations with immunotherapy (10:09)Treatment of oligoprogressive advanced breast cancer (17:31)CME information and select publications

Featuring perspectives from Dr David W Cescon, including the following topics:First-line treatment of metastatic triple-negative breast cancer (mTNBC) in patients not eligible for immunotherapy (0:00)First-line treatment of mTNBC in patients eligible for immunotherapy (12:05)Adverse events (19:39)CME information and select publications

Featuring perspectives from Dr Aditya Bardia, Dr Kevin Kalinsky and Dr Joyce O'Shaughnessy, including the following topics:Introduction (0:00)Hormone Receptor-Positive Breast Cancer — Dr Kalinsky (1:18)HER2-Positive Breast Cancer — Dr Bardia (42:46)Triple-Negative Breast Cancer — Dr O'Shaughnessy (1:01:41)CME information and select publications

Featuring perspectives from Dr Lisa A Carey and Dr Maha Hussain, including the following topics:Introduction (0:00)HER2 History (1:32)Cases from the GMO Survey (7:06)Biology and Selection of First-Line Therapy for HR-Positive, HER2-Positive Metastatic Breast Cancer (mBC) — Dr Mahtani (19:56)Faculty Case Presentations (31:37)Patterns of Care Survey — Part 1 (38:26)Optimizing the Use of Up-Front Maintenance Therapy for HER2-Positive mBC — Dr Carey (44:53)Faculty Case Presentations (54:13)CME information and select publications

Featuring perspectives from Prof Peter Schmid and Dr Melinda Telli, including the following topics:Introduction: TROP2-Targeting Antibody-Drug Conjugates (ADCs) for Metastatic Triple-Negative Breast Cancer (0:00)First-Line Therapy (PD-L1 Negative) (6:53)First-Line Therapy (PD-L1 Positive) (23:40)Second-Line Therapy (Sequencing) (34:08)Adverse Events with TROP2-Targeting ADCs (43:43)CME information and select publications

Featuring perspectives from Dr Virginia Kaklamani and Dr Hope S Rugo, including the following topics:Introduction: San Antonio Memories (0:00)PI3K/AKT/PTEN Alterations and Therapies (7:18)Capivasertib (20:22)Gedatolisib (34:08)Inavolisib (47:07)New Agents and Ongoing Trials (52:34)CME information and select publications